is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
Published 7 years ago • 435 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
2:10
phase ii study of epd maintenance after second autologous transplant for multiple myeloma
-
5:05
myeloma university | overview of autologous stem cell transplant for treatment of multiple myeloma
-
1:27
the use of salvage second autologous transplant in the age of novel therapies for multiple myeloma
-
1:53
transplantation for consolidation in multiple myeloma
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
18:16
recovering from a stem cell transplant
-
7:25
multiple myeloma stem cell transplant
-
1:57
the benefit of double autologous transplantation in multiple myeloma patient subgroups
-
1:48
the role of autologous transplantation in young and fit patients with multiple myeloma in 2022
-
4:13
benefit trial: isatuximab, lenalidomide, and dexamethasone /- bortezomib in newly diagnosed myeloma
-
1:30
the state of stem cell transplantation for multiple myeloma in brazil
-
1:58
with new treatment options in myeloma, is auto-sct still necessary?
-
1:36
the relevance of sct in multiple myeloma
-
2:22
the benefit of autologous transplantation in the era of novel agents in multiple myeloma
-
2:49
the importance of timing in autologous transplantation for multiple myeloma
-
0:43
why should autologous transplant remain the soc in myeloma?
-
1:23
indications for autologous stem cell transplantation in aml
-
1:43
feasibility of double autologous stem cell transplantation in patients with al amyloidosis
-
1:22
the potential use of car-t therapy following autologous transplantation in multiple myeloma
-
2:56
early vs. deferred transplantation in al amyloidosis
-
3:44
is double autologous transplantation in multiple myeloma superior in the age of new agents?